MedTrace Logo

18F-Floretyrosine Expanded Access Program

NCT06743100 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-04-02

No results posted yet for this study

Summary

The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to noninvasively detect tumor burden or treatment related change to assist in optimal management of patients with glioma.

Conditions

  • Glioma (Any Grade) in the Brain

Interventions

DIAGNOSTIC_TEST

18F-Floretyrosine

Single IV administration on Day 0, followed by a PET/CT or PET/MR diagnostic scan 20-40 minutes after the IV administration of 18F-Floretyrosine.

Sponsors & Collaborators

  • Telix Pharmaceuticals (Innovations) Pty Limited

    lead INDUSTRY

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06743100 on ClinicalTrials.gov